Over 110 expert speakers including senior representatives from Daiichi Sankyo, AstraZeneca, Pfizer, AbbVie, Merck, GSK, Johnson & Johnson, and ADC Therapeutics
Updated 5 tracks of scientific content covering development from bench to patient bedside, enabling you to take ADC from concept to approved therapy.
All exclusive 2025 plenary sessions covering the development of ADC blockbusters Enhertu, Luvelta, Zelenectide Pevedotin and HDP-101, evaluating new ADC formats and payloads in the clinic and understanding the clinical characteristics of ADC to maximise the therapeutic index.
Bonus seminar day and workshop day with sessions not to be missed, including an Introduction to ADC and the new Regulatory CMC Day.